查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2037521

寵物腫瘤市場預測至2034年－全球癌症類型、動物種類、治療方法、診斷方法、最終用戶、通路和區域分析

Pet Oncology Market Forecasts to 2034 - Global Analysis By Cancer Type, Animal Type, Therapy Type, Diagnosis Type, End User, Distribution Channel, and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的數據，預計到 2026 年，全球寵物腫瘤市場規模將達到 4.7 億美元，並在預測期內以 9.3% 的複合年成長率成長，到 2034 年將達到 9.7 億美元。

寵物腫瘤學是一個涵蓋癌症診斷、治療和管理的領域，主要針對犬貓等伴侶動物。獸醫學的水平正日益接近人類醫學。由於壽命延長、診斷技術進步以及環境因素的影響，寵物癌症的發生率不斷上升，使得腫瘤學成為獸醫學中至關重要的專科。這個領域涵蓋了專業機構提供的先進診斷方法、治療性介入和支持性護理，寵物飼主也越來越願意為他們心愛的寵物投入全面的癌症治療。

寵物越來越“擬人化”，飼主也越來越願意為寵物提供更高級的照顧。

寵物飼主越來越將心愛的寵物視為家庭成員，這導致對包括癌症治療在內的先進醫療服務的需求空前高漲。這種情感紐帶也帶來了沉重的經濟負擔，飼主不得不為寵物尋求化療、放療和先進手術等以往僅供人類患者使用的治療方案。寵物健康保險的普及進一步降低了經濟門檻，使寵物更容易獲得專業的腫瘤治療服務。隨著已開發市場居民可支配收入的成長以及人與動物之間情感紐帶的加深，獸醫診所報告稱，寵物主人對積極的癌症治療方案的接受度不斷提高，這從根本上擴大了全球寵物腫瘤治療服務的目標市場。

癌症診斷和治療高成本

儘管人們越來越願意投資動物健康，但全面的癌症治療所帶來的沉重經濟負擔仍然是許多寵物飼主面臨的主要障礙。先進的影像檢查、切片檢查分析、化療和放射線治療可能需要花費數千美元甚至更多，通常超出普通寵物保險的承保範圍。與人類醫療保健系統不同，獸醫領域缺乏政府補貼和全民健保，所有費用都直接由飼主承擔。這種經濟現實迫使飼主做出艱難的抉擇，有時不得不選擇安寧療護或安樂死，而不是昂貴但可能治癒的治療方法。因此，寵物醫療的市場滲透率有限，尤其是在價格敏感消費族群。

比較腫瘤學和轉化研究的進展

獸醫學與人類癌症研究之間日益密切的合作，為市場拓展和科學發現創造了巨大的機會。伴侶動物自然發生的癌症為研究腫瘤生物學和治療反應提供了寶貴的模型，這不僅加速了藥物研發，也直接造福了寵物患者。製藥公司擴大將獸醫試驗與人體研究相結合，認知到核准動物用藥品和獲取人體數據的雙重潛力。這種比較研究方法降低了研究成本和時間，同時增強了新療法的實證基礎。獸醫腫瘤學融入更廣泛的癌症研究生態系統，正在吸引投資、人才和創新，這些因素共同提升了該領域的專業水平和市場吸引力。

註冊獸醫腫瘤專家短缺

專科醫師嚴重短缺對市場成長構成重大威脅，儘管需求不斷成長，服務供應卻受到限制。由於培訓課程漫長，包括實習、住院醫師培訓以及獸醫學院畢業後的專科醫生資格認證考試，每年新增專科醫生數量有限。在鄉村和醫療資源匱乏地區，寵物飼主必須長途跋涉才能獲得腫瘤科會診，這項短缺問題尤其嚴重。病患需求與專科醫師供給之間的不平衡導致等待時間延長、會診時間縮短，以及後續照護品質下降。除非大幅擴展培訓計畫並引入創新的遠端醫療解決方案，否則這項短缺問題將繼續限制市場滿足日益成長的寵物癌症患者需求的能力。

新型冠狀病毒（COVID-19）的影響：

新冠疫情對寵物腫瘤市場產生了複雜的影響。初期，市場受到衝擊，但隨後某些趨勢穩定加速發展。封鎖措施暫時減少了寵物的常規就診次數，並推遲了非緊急癌症篩檢，同時，寵物領養數量增加，加強了人與動物之間的聯繫。遠端醫療的普及使得遠距諮詢和後續觀察成為可能，從而突破了地理限制，擴大了腫瘤專科服務的覆蓋範圍。疫情凸顯了寵物的健康脆弱性，提高了飼主對寵物健康的關注度，並增強了他們對癌症預防和早期檢測的重視。這些行為改變得以延續，即使在疫情結束後，寵物飼主仍然保持著對寵物健康的高度關注，並且越來越接受腫瘤診療中以技術驅動的醫療服務模式。

在預測期內，影像產業預計將佔據最大的市場佔有率。

預計在預測期內，診斷成像領域將佔據最大的市場佔有率。這反映了放射影像在癌症診斷和分期中的關鍵作用。包括電腦斷層掃描 (CT)、磁振造影(MRI)、超音波和放射成像在內的先進成像技術，能夠提供關於腫瘤位置、大小、轉移狀態和解剖關係的重要信息，這些資訊對於治療方案的發展至關重要。隨著轉診醫院和專科中心不斷提升自身能力，獸醫院也增加對先進影像設備的投入。鑑於大多數影像技術都是非侵入性的，並且能夠指導切片檢查手術和監測治療效果，這些診斷工具必將在整個預測期內繼續成為獸醫腫瘤學實踐的基礎。

在預測期內，「專科癌症中心」細分市場預計將呈現最高的複合年成長率。

在預測期內，「專科腫瘤中心」細分市場預計將呈現最高的成長率，這主要得益於人們對在同一機構內獲得全面、多學科腫瘤治療的需求不斷成長。這些專科中心配備了專業的腫瘤團隊，協調提供包括影像、切片檢查、化療、放射線治療、手術和安寧療護在內的綜合服務。由於這些中心擁有先進的醫療能力、參與臨床試驗的機會以及持續的護理，寵物飼主越來越傾向於選擇這些中心而不是普通獸醫診所。昂貴的設備和專業人員集中在專門的設施中，提高了營運效率和臨床療效。隨著私募股權投資流入獸醫專科領域以及轉診網路的擴展，這些中心在主要大都會圈市場蓬勃發展。

市佔率最大的地區：

在預測期內，北美預計將佔據最大的市場佔有率，這得益於其較高的寵物擁有率、先進的獸醫基礎設施以及飼主對專業護理的強烈投資意願。該地區成熟的寵物保險市場降低了經濟門檻，而廣泛的轉診醫院和專科中心網路則確保了都市區和郊區的地域覆蓋。頂尖的獸醫學院和研究機構正在推動腫瘤診斷和治療方法的持續創新。媒體對動物癌症成功案例的報導，提高了社會對先進寵物癌症治療的接受度，並鼓勵飼主選擇積極的治療方案。這些結構性優勢預計將使北美在整個預測期內保持其市場主導地位。

複合年成長率最高的地區：

在預測期內，亞太地區預計將呈現最高的複合年成長率，這主要得益於寵物擁有量的激增、可支配收入的提高以及西方對寵物護理意識的日益增強。隨著都市化導致家庭規模縮小，越來越多的家庭開始飼養寵物，中國、日本和韓國等國家的人與動物關係正在發生根本性的變化。主要城市中專業獸醫醫院的建立，以及寵物保險的普及，正在改善寵物獲得先進腫瘤治療服務的途徑。政府對獸醫基礎設施的投資以及訓練有素的專科醫生數量的增加，正在緩解長期存在的勞動力短缺問題。隨著社群媒體和國際旅行的普及，人們對寵物癌症治療方法方案的認知不斷提高，亞太地區正成為寵物腫瘤治療服務成長最快的市場。

免費客製化服務：

所有購買此報告的客戶均可享受以下免費自訂選項之一：

  • 企業概況
    • 對其他市場參與者（最多 3 家公司）進行全面分析
    • 對主要公司進行SWOT分析（最多3家公司）
  • 區域細分
    • 應客戶要求，我們提供主要國家的市場估算和預測，以及複合年成長率（註：需進行可行性檢查）。
  • 競爭性標竿分析
    • 根據產品系列、地理覆蓋範圍和策略聯盟對領先公司進行基準分析。

目錄

第1章執行摘要

  • 市場概覽及主要亮點
  • 促進因素、挑戰與機遇
  • 競爭格局概述
  • 戰略洞察與建議

第2章：研究框架

  • 研究目標和範圍
  • 相關人員分析
  • 研究假設和限制
  • 調查方法

第3章 市場動態與趨勢分析

  • 市場定義與結構
  • 主要市場促進因素
  • 市場限制與挑戰
  • 投資成長機會和重點領域
  • 產業威脅與風險評估
  • 技術與創新展望
  • 新興市場/高成長市場
  • 監管和政策環境
  • 新冠疫情的影響及復甦前景

第4章：競爭環境與策略評估

  • 波特五力分析
    • 供應商的議價能力
    • 買方的議價能力
    • 替代品的威脅
    • 新進入者的威脅
    • 競爭公司之間的競爭
  • 主要公司市佔率分析
  • 產品基準評效和效能比較

第5章：全球寵物腫瘤市場：依癌症類型分類

  • 淋巴瘤
  • 肥大細胞瘤
  • 黑色素瘤
  • 鱗狀細胞癌
  • 乳腺/皮膚腫瘤
  • 其他癌症

第6章：全球寵物腫瘤市場：依動物類型分類

  • 狗
  • 貓
  • 其他伴侶動物

第7章：全球寵物腫瘤市場：依治療方法

  • 化療
  • 放射線治療
  • 免疫療法
  • 標靶治療
  • 外科手術
  • 聯合治療

第8章：全球寵物腫瘤市場：依診斷類型分類

  • 切片檢查
  • 診斷影像
  • 驗血
  • 分子診斷
  • 其他診斷方法

第9章：全球寵物腫瘤市場：依最終用戶分類

  • 獸醫醫院和診所
  • 專科癌症中心
  • 學術研究機構

第10章：全球寵物腫瘤市場：依通路分類

  • 獸藥
  • 網路藥房
  • 零售藥房

第11章 全球寵物腫瘤市場：按地區分類

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 荷蘭
    • 比利時
    • 瑞典
    • 瑞士
    • 波蘭
    • 其他歐洲國家
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
    • 印尼
    • 泰國
    • 馬來西亞
    • 新加坡
    • 越南
    • 其他亞太國家
  • 南美洲
    • 巴西
    • 阿根廷
    • 哥倫比亞
    • 智利
    • 秘魯
    • 其他南美國家
  • 世界其他地區（RoW）
    • 中東
      • 沙烏地阿拉伯
      • 阿拉伯聯合大公國
      • 卡達
      • 以色列
      • 其他中東國家
    • 非洲
      • 南非
      • 埃及
      • 摩洛哥
      • 其他非洲國家

第12章 策略市場資訊

  • 工業價值網路和供應鏈評估
  • 空白區域和機會地圖
  • 產品演進與市場生命週期分析
  • 通路、經銷商和打入市場策略的評估

第13章 產業趨勢與策略舉措

  • 併購
  • 夥伴關係、聯盟和合資企業
  • 新產品發布和認證
  • 擴大生產能力和投資
  • 其他策略舉措

第14章：公司簡介

  • Zoetis Inc
  • Elanco Animal Health Incorporated
  • Virbac
  • Boehringer Ingelheim International GmbH
  • Dechra Pharmaceuticals PLC
  • VCA Inc
  • PetCure Oncology
  • Varian Medical Systems Inc
  • Accuray Incorporated
  • Elekta AB
  • Merck & Co Inc
  • Ceva Sante Animale
  • Aratana Therapeutics Inc
  • Phibro Animal Health Corporation
  • Heska Corporation
Product Code: SMRC35935

According to Stratistics MRC, the Global Pet Oncology Market is accounted for $0.47 billion in 2026 and is expected to reach $0.97 billion by 2034 growing at a CAGR of 9.3% during the forecast period. Pet oncology encompasses the diagnosis, treatment, and management of cancer in companion animals, primarily dogs and cats, as veterinary medicine increasingly mirrors human healthcare capabilities. The rising incidence of cancer in pets, driven by longer lifespans, improved diagnostics, and environmental factors, has elevated oncology to a critical specialty within veterinary practice. This market includes advanced diagnostic modalities, therapeutic interventions, and supportive care services delivered across specialized facilities, with pet owners demonstrating growing willingness to invest in comprehensive cancer care for their animal companions.

Market Dynamics:

Driver:

Increasing pet humanization and owner willingness to spend on advanced care

Pet owners increasingly view their animal companions as family members, driving unprecedented demand for sophisticated medical treatments including cancer care. This emotional bond translates into substantial financial commitments, with owners pursuing therapies such as chemotherapy, radiation, and advanced surgery that were once reserved exclusively for human patients. The availability of pet health insurance has further reduced economic barriers, enabling access to specialty oncology services. As disposable incomes rise across developed markets and the human-animal bond strengthens, veterinary practices report growing acceptance of aggressive cancer treatment protocols, fundamentally expanding the addressable market for pet oncology services worldwide.

Restraint:

High cost of cancer diagnostics and treatments

The substantial financial burden of comprehensive cancer care remains a significant barrier for many pet owners despite growing willingness to invest in animal health. Advanced imaging procedures, biopsy analysis, chemotherapy protocols, and radiation therapy can accumulate costs exceeding several thousand dollars, often exceeding typical pet insurance coverage limits. Unlike human healthcare systems, veterinary medicine lacks government subsidies or universal coverage, placing the entire financial responsibility directly on owners. This economic reality forces difficult decisions, with some owners opting for palliative care or euthanasia rather than pursuing potentially curative but expensive treatment pathways, limiting market penetration particularly in price-sensitive demographic segments.

Opportunity:

Advancements in comparative oncology and translational research

Growing collaboration between veterinary and human oncology research is creating significant opportunities for market expansion and scientific discovery. Naturally occurring cancers in companion animals provide valuable models for studying tumor biology and therapeutic responses, accelerating drug development while directly benefiting pet patients. Pharmaceutical companies increasingly include veterinary trials alongside human studies, recognizing the dual potential for animal health approvals and human data generation. This comparative approach reduces research costs and timelines while strengthening the evidence base for novel therapeutics. Veterinary oncology's integration into broader cancer research ecosystems attracts investment, talent, and technological innovation that collectively advance the specialty's capabilities and market appeal.

Threat:

Shortage of board-certified veterinary oncologists

A severe scarcity of specialized professionals poses a critical threat to market growth, limiting service availability despite rising demand. The extensive training pathway, requiring veterinary school completion followed by internship, residency, and board certification examinations, produces only a small number of new specialists annually. This workforce gap disproportionately affects rural and underserved regions where pet owners must travel substantial distances for oncology consultations. The imbalance between patient demand and specialist availability creates extended wait times, rushed appointments, and compromised continuity of care. Without significant expansion of training programs and innovative telemedicine solutions, this workforce constraint will continue constraining the market's ability to serve the growing cancer-afflicted pet population.

Covid-19 Impact:

The COVID-19 pandemic produced mixed effects on the pet oncology market, with initial disruptions followed by sustained acceleration of certain trends. Lockdowns temporarily reduced routine veterinary visits and delayed non-urgent cancer screenings, while also increasing pet adoptions and strengthening human-animal bonds. Telemedicine adoption surged, enabling remote consultations and follow-up care that expanded access to oncology expertise beyond geographic limitations. The pandemic's emphasis on health vulnerability heightened owner awareness of pet wellness, including cancer prevention and early detection. These behavioral shifts proved durable, with post-pandemic pet owners maintaining heightened vigilance about animal health and greater acceptance of technology-enabled care delivery models in oncology practice.

The Imaging segment is expected to be the largest during the forecast period

The Imaging segment is expected to account for the largest market share during the forecast period, reflecting the essential role of radiographic visualization in cancer diagnosis and staging. Advanced imaging modalities including computed tomography (CT), magnetic resonance imaging (MRI), ultrasound, and radiography provide critical information about tumor location, size, metastasis status, and anatomical relationships essential for treatment planning. Veterinary practices have increasingly invested in sophisticated imaging equipment as referral hospitals and specialty centers expand their capabilities. The non-invasive nature of most imaging procedures, combined with their ability to guide biopsy procedures and monitor therapeutic response, ensures these diagnostic tools remain foundational to pet oncology practice throughout the forecast timeline.

The Specialty Cancer Centers segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the Specialty Cancer Centers segment is predicted to witness the highest growth rate, driven by the increasing demand for comprehensive, multidisciplinary oncology care under one roof. These dedicated facilities offer integrated services including diagnostic imaging, biopsy, chemotherapy administration, radiation therapy, surgery, and palliative care, coordinated by specialized oncology teams. Pet owners increasingly prefer these centers for their advanced capabilities, clinical trial access, and continuity of care compared to general veterinary practices. The concentration of expensive equipment and specialized personnel in dedicated facilities improves operational efficiency and clinical outcomes. As private equity investment flows into veterinary specialty medicine and referral networks expand, these centers are proliferating across major metropolitan markets.

Region with largest share:

During the forecast period, the North America region is expected to hold the largest market share, supported by high pet ownership rates, advanced veterinary infrastructure, and strong owner willingness to invest in specialty care. The region's mature pet insurance market reduces financial barriers, while extensive networks of referral hospitals and specialty centers ensure geographic coverage across urban and suburban areas. Leading veterinary schools and research institutions drive continuous innovation in oncology diagnostics and therapeutics. The cultural normalization of advanced pet cancer treatment, reinforced by media coverage of successful animal cancer cases, encourages owners to pursue aggressive treatment pathways. These structural advantages collectively sustain North America's dominant market position throughout the forecast period.

Region with highest CAGR:

Over the forecast period, the Asia Pacific region is anticipated to exhibit the highest CAGR, fueled by rapidly rising pet ownership, growing disposable incomes, and increasing Western influence on pet care attitudes. Countries including China, Japan, and South Korea are witnessing fundamental shifts in human-animal relationships as urbanization reduces family sizes and more households welcome companion animals. The establishment of veterinary specialty hospitals in major cities, combined with expanding pet insurance availability, improves access to advanced oncology services. Government investments in veterinary infrastructure and rising numbers of trained specialists address historical workforce constraints. As awareness of pet cancer treatment options spreads through social media and international travel, Asia Pacific emerges as the fastest-growing market for pet oncology services.

Key players in the market

Some of the key players in Pet Oncology Market include Zoetis Inc, Elanco Animal Health Incorporated, Virbac, Boehringer Ingelheim International GmbH, Dechra Pharmaceuticals PLC, VCA Inc, PetCure Oncology, Varian Medical Systems Inc, Accuray Incorporated, Elekta AB, Merck & Co Inc, Ceva Sante Animale, Aratana Therapeutics Inc, Phibro Animal Health Corporation, and Heska Corporation.

Key Developments:

In February 2026, PetCure Oncology announced the successful treatment of the first canine patient using the Sirius(TM) robotically accelerated platform at its Seattle location, marking the first use of human-grade PAWS-RT (Photon Augmented Wave Stereotactic Radiation Therapy) in the Pacific Northwest.

In January 2026, Zoetis launched a new AI-powered diagnostic module for its Vetscan Imagyst(TM) platform, specifically designed to help veterinarians identify cancerous cells in fine-needle aspirates with higher accuracy at the point of care.

In October 2025, Elanco received final regulatory approval for Befrena, a novel therapeutic aimed at managing specialty conditions in pets, strengthening its position in the high-margin therapeutic market.

Cancer Types Covered:

  • Lymphoma
  • Mast Cell Tumors
  • Melanoma
  • Squamous Cell Carcinoma
  • Mammary & Skin Tumors
  • Other Cancer Types

Animal Types Covered:

  • Dogs
  • Cats
  • Other Companion Animals

Therapy Types Covered:

  • Chemotherapy
  • Radiation Therapy
  • Immunotherapy
  • Targeted Therapy
  • Surgery
  • Combination Therapy

Diagnostic Types Covered:

  • Biopsy
  • Imaging
  • Blood Tests
  • Molecular Diagnostics
  • Other Diagnostic Methods

End Users Covered:

  • Veterinary Hospitals & Clinics
  • Specialty Cancer Centers
  • Academic & Research Institutes

Distribution Channels Covered:

  • Veterinary Pharmacies
  • Online Pharmacies
  • Retail Pharmacies

Regions Covered:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • United Kingdom
    • Germany
    • France
    • Italy
    • Spain
    • Netherlands
    • Belgium
    • Sweden
    • Switzerland
    • Poland
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Thailand
    • Malaysia
    • Singapore
    • Vietnam
    • Rest of Asia Pacific
  • South America
    • Brazil
    • Argentina
    • Colombia
    • Chile
    • Peru
    • Rest of South America
  • Rest of the World (RoW)
    • Middle East
  • Saudi Arabia
  • United Arab Emirates
  • Qatar
  • Israel
  • Rest of Middle East
    • Africa
  • South Africa
  • Egypt
  • Morocco
  • Rest of Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2023, 2024, 2025, 2026, 2027, 2028, 2030, 2032 and 2034
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

  • 1.1 Market Snapshot and Key Highlights
  • 1.2 Growth Drivers, Challenges, and Opportunities
  • 1.3 Competitive Landscape Overview
  • 1.4 Strategic Insights and Recommendations

2 Research Framework

  • 2.1 Study Objectives and Scope
  • 2.2 Stakeholder Analysis
  • 2.3 Research Assumptions and Limitations
  • 2.4 Research Methodology
    • 2.4.1 Data Collection (Primary and Secondary)
    • 2.4.2 Data Modeling and Estimation Techniques
    • 2.4.3 Data Validation and Triangulation
    • 2.4.4 Analytical and Forecasting Approach

3 Market Dynamics and Trend Analysis

  • 3.1 Market Definition and Structure
  • 3.2 Key Market Drivers
  • 3.3 Market Restraints and Challenges
  • 3.4 Growth Opportunities and Investment Hotspots
  • 3.5 Industry Threats and Risk Assessment
  • 3.6 Technology and Innovation Landscape
  • 3.7 Emerging and High-Growth Markets
  • 3.8 Regulatory and Policy Environment
  • 3.9 Impact of COVID-19 and Recovery Outlook

4 Competitive and Strategic Assessment

  • 4.1 Porter's Five Forces Analysis
    • 4.1.1 Supplier Bargaining Power
    • 4.1.2 Buyer Bargaining Power
    • 4.1.3 Threat of Substitutes
    • 4.1.4 Threat of New Entrants
    • 4.1.5 Competitive Rivalry
  • 4.2 Market Share Analysis of Key Players
  • 4.3 Product Benchmarking and Performance Comparison

5 Global Pet Oncology Market, By Cancer Type

  • 5.1 Lymphoma
  • 5.2 Mast Cell Tumors
  • 5.3 Melanoma
  • 5.4 Squamous Cell Carcinoma
  • 5.5 Mammary & Skin Tumors
  • 5.6 Other Cancer Types

6 Global Pet Oncology Market, By Animal Type

  • 6.1 Dogs
  • 6.2 Cats
  • 6.3 Other Companion Animals

7 Global Pet Oncology Market, By Therapy Type

  • 7.1 Chemotherapy
  • 7.2 Radiation Therapy
  • 7.3 Immunotherapy
  • 7.4 Targeted Therapy
  • 7.5 Surgery
  • 7.6 Combination Therapy

8 Global Pet Oncology Market, By Diagnosis Type

  • 8.1 Biopsy
  • 8.2 Imaging
  • 8.3 Blood Tests
  • 8.4 Molecular Diagnostics
  • 8.5 Other Diagnostic Methods

9 Global Pet Oncology Market, By End User

  • 9.1 Veterinary Hospitals & Clinics
  • 9.2 Specialty Cancer Centers
  • 9.3 Academic & Research Institutes

10 Global Pet Oncology Market, By Distribution Channel

  • 10.1 Veterinary Pharmacies
  • 10.2 Online Pharmacies
  • 10.3 Retail Pharmacies

11 Global Pet Oncology Market, By Geography

  • 11.1 North America
    • 11.1.1 United States
    • 11.1.2 Canada
    • 11.1.3 Mexico
  • 11.2 Europe
    • 11.2.1 United Kingdom
    • 11.2.2 Germany
    • 11.2.3 France
    • 11.2.4 Italy
    • 11.2.5 Spain
    • 11.2.6 Netherlands
    • 11.2.7 Belgium
    • 11.2.8 Sweden
    • 11.2.9 Switzerland
    • 11.2.10 Poland
    • 11.2.11 Rest of Europe
  • 11.3 Asia Pacific
    • 11.3.1 China
    • 11.3.2 Japan
    • 11.3.3 India
    • 11.3.4 South Korea
    • 11.3.5 Australia
    • 11.3.6 Indonesia
    • 11.3.7 Thailand
    • 11.3.8 Malaysia
    • 11.3.9 Singapore
    • 11.3.10 Vietnam
    • 11.3.11 Rest of Asia Pacific
  • 11.4 South America
    • 11.4.1 Brazil
    • 11.4.2 Argentina
    • 11.4.3 Colombia
    • 11.4.4 Chile
    • 11.4.5 Peru
    • 11.4.6 Rest of South America
  • 11.5 Rest of the World (RoW)
    • 11.5.1 Middle East
      • 11.5.1.1 Saudi Arabia
      • 11.5.1.2 United Arab Emirates
      • 11.5.1.3 Qatar
      • 11.5.1.4 Israel
      • 11.5.1.5 Rest of Middle East
    • 11.5.2 Africa
      • 11.5.2.1 South Africa
      • 11.5.2.2 Egypt
      • 11.5.2.3 Morocco
      • 11.5.2.4 Rest of Africa

12 Strategic Market Intelligence

  • 12.1 Industry Value Network and Supply Chain Assessment
  • 12.2 White-Space and Opportunity Mapping
  • 12.3 Product Evolution and Market Life Cycle Analysis
  • 12.4 Channel, Distributor, and Go-to-Market Assessment

13 Industry Developments and Strategic Initiatives

  • 13.1 Mergers and Acquisitions
  • 13.2 Partnerships, Alliances, and Joint Ventures
  • 13.3 New Product Launches and Certifications
  • 13.4 Capacity Expansion and Investments
  • 13.5 Other Strategic Initiatives

14 Company Profiles

  • 14.1 Zoetis Inc
  • 14.2 Elanco Animal Health Incorporated
  • 14.3 Virbac
  • 14.4 Boehringer Ingelheim International GmbH
  • 14.5 Dechra Pharmaceuticals PLC
  • 14.6 VCA Inc
  • 14.7 PetCure Oncology
  • 14.8 Varian Medical Systems Inc
  • 14.9 Accuray Incorporated
  • 14.10 Elekta AB
  • 14.11 Merck & Co Inc
  • 14.12 Ceva Sante Animale
  • 14.13 Aratana Therapeutics Inc
  • 14.14 Phibro Animal Health Corporation
  • 14.15 Heska Corporation

List of Tables

  • Table 1 Global Pet Oncology Market Outlook, By Region (2023-2034) ($MN)
  • Table 2 Global Pet Oncology Market Outlook, By Cancer Type (2023-2034) ($MN)
  • Table 3 Global Pet Oncology Market Outlook, By Lymphoma (2023-2034) ($MN)
  • Table 4 Global Pet Oncology Market Outlook, By Mast Cell Tumors (2023-2034) ($MN)
  • Table 5 Global Pet Oncology Market Outlook, By Melanoma (2023-2034) ($MN)
  • Table 6 Global Pet Oncology Market Outlook, By Squamous Cell Carcinoma (2023-2034) ($MN)
  • Table 7 Global Pet Oncology Market Outlook, By Mammary & Skin Tumors (2023-2034) ($MN)
  • Table 8 Global Pet Oncology Market Outlook, By Other Cancer Types (2023-2034) ($MN)
  • Table 9 Global Pet Oncology Market Outlook, By Animal Type (2023-2034) ($MN)
  • Table 10 Global Pet Oncology Market Outlook, By Dogs (2023-2034) ($MN)
  • Table 11 Global Pet Oncology Market Outlook, By Cats (2023-2034) ($MN)
  • Table 12 Global Pet Oncology Market Outlook, By Other Companion Animals (2023-2034) ($MN)
  • Table 13 Global Pet Oncology Market Outlook, By Therapy Type (2023-2034) ($MN)
  • Table 14 Global Pet Oncology Market Outlook, By Chemotherapy (2023-2034) ($MN)
  • Table 15 Global Pet Oncology Market Outlook, By Radiation Therapy (2023-2034) ($MN)
  • Table 16 Global Pet Oncology Market Outlook, By Immunotherapy (2023-2034) ($MN)
  • Table 17 Global Pet Oncology Market Outlook, By Targeted Therapy (2023-2034) ($MN)
  • Table 18 Global Pet Oncology Market Outlook, By Surgery (2023-2034) ($MN)
  • Table 19 Global Pet Oncology Market Outlook, By Combination Therapy (2023-2034) ($MN)
  • Table 20 Global Pet Oncology Market Outlook, By Diagnosis Type (2023-2034) ($MN)
  • Table 21 Global Pet Oncology Market Outlook, By Biopsy (2023-2034) ($MN)
  • Table 22 Global Pet Oncology Market Outlook, By Imaging (2023-2034) ($MN)
  • Table 23 Global Pet Oncology Market Outlook, By Blood Tests (2023-2034) ($MN)
  • Table 24 Global Pet Oncology Market Outlook, By Molecular Diagnostics (2023-2034) ($MN)
  • Table 25 Global Pet Oncology Market Outlook, By Other Diagnostic Methods (2023-2034) ($MN)
  • Table 26 Global Pet Oncology Market Outlook, By End User (2023-2034) ($MN)
  • Table 27 Global Pet Oncology Market Outlook, By Veterinary Hospitals & Clinics (2023-2034) ($MN)
  • Table 28 Global Pet Oncology Market Outlook, By Specialty Cancer Centers (2023-2034) ($MN)
  • Table 29 Global Pet Oncology Market Outlook, By Academic & Research Institutes (2023-2034) ($MN)
  • Table 30 Global Pet Oncology Market Outlook, By Distribution Channel (2023-2034) ($MN)
  • Table 31 Global Pet Oncology Market Outlook, By Veterinary Pharmacies (2023-2034) ($MN)
  • Table 32 Global Pet Oncology Market Outlook, By Online Pharmacies (2023-2034) ($MN)
  • Table 33 Global Pet Oncology Market Outlook, By Retail Pharmacies (2023-2034) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Rest of the World (RoW) Regions are also represented in the same manner as above.